The hope is that remdesivir will show better results with the coronavirus than it did with Ebola, which is from a different viral family, officials said. ADThe potential patient pool for clinical trials dries up once a new infectious outbreak subsides, so investment can be frozen in partly completed projects. Gilead said it donates free drug samples for the government-funded research of remdesivir and helps design scientific studies and clinical trials. “Drug companies don’t have an interest in emerging infectious diseases,’’ he said. The drug has not been studied in human trials for SARS or MERS, because there are not enough patients, Gilead said.

Source: Washington Post March 11, 2020 14:32 UTC